Literature DB >> 19741030

Study of prone positioning to reduce ventilator-associated pneumonia in hypoxaemic patients.

R Mounier1, C Adrie, A Français, M Garrouste-Orgeas, C Cheval, B Allaouchiche, S Jamali, A T Dinh-Xuan, D Goldgran-Toledano, Y Cohen, E Azoulay, J-F Timsit, J-D Ricard.   

Abstract

The aim of the present study was to examine whether prone positioning (PP) affects ventilator associated-pneumonia (VAP) and mortality in patients with acute lung injury/adult respiratory distress syndrome. 2,409 prospectively included patients were admitted over 9 yrs (2000-2008) to 12 French intensive care units (ICUs) (OUTCOMEREA). The patients required invasive mechanical ventilation (MV) and had arterial oxygen tension/inspiratory oxygen fraction ratios <300 during the first 48 h. Controls were matched to PP patients on the PP propensity score (+/-10%), MV duration longer than that in PP patients before the first turn prone, and centre. VAP incidence was similar in the PP and control groups (24 versus 13 episodes.1,000 patient-days MV(-1) respectively, p = 0.14). After adjustment, PP did not decrease VAP occurrence (HR 1.64 (95% CI 0.70-3.84); p = 0.25) but significantly delayed hospital mortality (HR 0.56 (95% CI 0.39-0.79); p = 0.001), without decreasing 28-day mortality (37% in both groups). Post hoc analyses indicated that PP did not protect against VAP but, when used for >1 day, might decrease mortality and benefit the sickest patients (Simplified Acute Physiology Score >50). In ICU patients with hypoxaemic acute respiratory failure, PP had no effect on the risk of VAP. PP delayed mortality without decreasing 28-day mortality. PP >1 day might decrease mortality, particularly in the sickest patients.

Entities:  

Mesh:

Year:  2009        PMID: 19741030     DOI: 10.1183/09031936.00057509

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  [Short version S2e guidelines: "Positioning therapy and early mobilization for prophylaxis or therapy of pulmonary function disorders"].

Authors:  T Bein; M Bischoff; U Brückner; K Gebhardt; D Henzler; C Hermes; K Lewandowski; M Max; M Nothacker; T Staudinger; M Tryba; S Weber-Carstens; H Wrigge
Journal:  Anaesthesist       Date:  2015-08       Impact factor: 1.041

2.  Ventilator-associated pneumonia in ARDS patients: the impact of prone positioning. A secondary analysis of the PROSEVA trial.

Authors:  L Ayzac; R Girard; L Baboi; P Beuret; M Rabilloud; J C Richard; C Guérin
Journal:  Intensive Care Med       Date:  2015-12-23       Impact factor: 17.440

3.  Prone position acute respiratory distress syndrome patients: less prone to ventilator associated pneumonia?

Authors:  H Dupont; P Depuydt; F Abroug
Journal:  Intensive Care Med       Date:  2016-01-14       Impact factor: 17.440

Review 4.  The Role of Dysbiosis in Critically Ill Patients With COVID-19 and Acute Respiratory Distress Syndrome.

Authors:  Denise Battaglini; Chiara Robba; Andrea Fedele; Sebastian Trancǎ; Samir Giuseppe Sukkar; Vincenzo Di Pilato; Matteo Bassetti; Daniele Roberto Giacobbe; Antonio Vena; Nicolò Patroniti; Lorenzo Ball; Iole Brunetti; Antoni Torres Martí; Patricia Rieken Macedo Rocco; Paolo Pelosi
Journal:  Front Med (Lausanne)       Date:  2021-06-04

5.  S2e guideline: positioning and early mobilisation in prophylaxis or therapy of pulmonary disorders : Revision 2015: S2e guideline of the German Society of Anaesthesiology and Intensive Care Medicine (DGAI).

Authors:  Th Bein; M Bischoff; U Brückner; K Gebhardt; D Henzler; C Hermes; K Lewandowski; M Max; M Nothacker; Th Staudinger; M Tryba; S Weber-Carstens; H Wrigge
Journal:  Anaesthesist       Date:  2015-12       Impact factor: 1.041

Review 6.  Pulmonary infections complicating ARDS.

Authors:  Charles-Edouard Luyt; Lila Bouadma; Andrew Conway Morris; Jayesh A Dhanani; Marin Kollef; Jeffrey Lipman; Ignacio Martin-Loeches; Saad Nseir; Otavio T Ranzani; Antoine Roquilly; Matthieu Schmidt; Antoni Torres; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2020-11-11       Impact factor: 17.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.